Complete and Sustained Response with a Doublet Chemotherapy Protocol in an 81-Year-Old Patient with Metastatic Breast Cancer

Metastatic breast cancer (MBC) entails an overall 5-year survival of approximately 25%. The choice of therapy is influenced by expression of the HER2 gene and hormone receptors, by a disease-free interval, and by age. The use of paclitaxel combined with gemcitabine (doublet protocol) has shown effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Puty, Taynah Cascaes, Brito, Gabriel S.A., Dias, Mariana S., Miranda, Henrique C., Chaves, Juliana R., Freitas, Heryvelton L., Carvalho, Luís E.W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118833/
https://www.ncbi.nlm.nih.gov/pubmed/27920688
http://dx.doi.org/10.1159/000449127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118833/
https://www.ncbi.nlm.nih.gov/pubmed/27920688
http://dx.doi.org/10.1159/000449127

Ejemplares similares